VC giant NEA brings in life sciences veteran Park as newest partner


Venture capital major New Enterprise Associates has brought in veteran life sciences investor Michele Park as a partner in its Menlo Park office.

Park joins NEA after 15 years as an investor at Clarus Ventures, where she served as a board director and member for a string of biopharmaceutical companies.

NEA healthcare general managing partner Mohamad Makhzoumi said, “We are thrilled to welcome Michele to NEA and are confident that her extensive experience as a life sciences investor will be an asset to our investing team and portfolio companies alike.

“We’ve seen firsthand through our shared investments how Michele works closely with biopharmaceutical companies across various stages, and both her scientific and company-building experience put her in a great position to be a valuable contributor to NEA’s healthcare investing practice.”

NEA’s healthcare portfolio includes renowned biopharma companies such as Tesaro and CRISPR Therapeutics, as well as digital health companies attempting to create new models for care delivery, such as Bright Health, Everside Health and Radiology Partners.

As Partner at Clarus Ventures – now Blackstone Life Sciences – Park led the initiative to launch the Clarus Cancer Fund, designed to generate returns and fuel cancer research through donation.

Prior to Clarus she spent six years as a research analyst covering the biotechnology sector at Credit Suisse and Piper Jaffray.

NEA raised $3.6bn for the final close of its 17th venture fund last year.

Copyright © 2021 AltAssets

Get the latest PE News & Research delivered to your inbox every morning